Literature DB >> 28867373

Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.

Xiaodong Li1, Longchuan Yu2, Frank Asuncion2, Mario Grisanti2, Shawn Alexander2, Kelly Hensley3, Chun-Ya Han2, Qing-Tian Niu2, Denise Dwyer2, Kelly Villasenor2, Marina Stolina2, Charles Dean3, Michael S Ominsky2, Hua Zhu Ke2, James E Tomlinson2, William G Richards2.   

Abstract

Sustained elevation of parathyroid hormone (PTH) is catabolic to cortical bone, as evidenced by deterioration in bone structure (cortical porosity), and is a major factor for increased fracture risk in chronic kidney disease (CKD). Etelcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces PTH levels in subtotal nephrectomized (Nx) rats and in hemodialysis patients with secondary hyperparathyroidism (SHPT) in clinical studies; however, effects of etelcalcetide on bone have not been determined. In a rat model of established SHPT with renal osteodystrophy, etelcalcetide or vehicle was administered by subcutaneous (s.c.) injection to subtotal Nx rats with elevated PTH (>750pg/mL) once per day for 6weeks. Sham-operated rats receiving vehicle (s.c.) served as non-SHPT controls. Prior to treatment, significant increases in serum creatinine (2-fold), blood urea nitrogen (BUN, 3-fold), PTH (5-fold), fibroblast growth factor-23 (FGF23; 13-fold) and osteocalcin (12-fold) were observed in SHPT rats compared to non-SHPT controls. Elevations in serum creatinine and BUN were unaffected by treatment with vehicle or etelcalcetide. In contrast, etelcalcetide significantly decreased PTH, FGF23 and osteocalcin, whereas vehicle treatment did not. Cortical bone porosity increased and bone strength decreased in vehicle-treated SHPT rats compared to non-SHPT controls. Cortical bone structure improved and energy to failure was significantly greater in SHPT rats treated with etelcalcetide compared to vehicle. Mineralization lag time and marrow fibrosis were significantly reduced by etelcalcetide. In conclusion, etelcalcetide reduced bone turnover, attenuated mineralization defect and marrow fibrosis, and preserved cortical bone structure and bone strength by lowering PTH in subtotal Nx rats with established SHPT.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone turnover; Calcium-sensing receptor agonist; Cortical porosity; FGF23; Secondary hyperparathyroidism

Mesh:

Substances:

Year:  2017        PMID: 28867373     DOI: 10.1016/j.bone.2017.08.026

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  4 in total

Review 1.  Old and New Drugs for the Management of Bone Disorders in CKD.

Authors:  Hirotaka Komaba; Markus Ketteler; John Cunningham; Masafumi Fukagawa
Journal:  Calcif Tissue Int       Date:  2021-01-02       Impact factor: 4.333

2.  Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics.

Authors:  Maria Dolores Arenas; Cristian Rodelo-Haad; M Victoria Pendón-Ruiz de Mier; Mariano Rodriguez
Journal:  Clin Kidney J       Date:  2020-02-12

Review 3.  Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy.

Authors:  Claudia Friedl; Emanuel Zitt
Journal:  Drug Des Devel Ther       Date:  2018-06-01       Impact factor: 4.162

Review 4.  2017 FDA Peptide Harvest.

Authors:  Othman Al Musaimi; Danah Al Shaer; Beatriz G de la Torre; Fernando Albericio
Journal:  Pharmaceuticals (Basel)       Date:  2018-05-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.